Only 15-29% of exenatide's cardiovascular benefits in the EXSCEL trial could be explained by improvements in traditional risk factors like blood sugar, blood pressure, and cholesterol — meaning most of the heart protection comes from something else.
Only 15% of mortality benefit explainedTraditional risk factor improvements (blood sugar, blood pressure, cholesterol, weight) account for just 15% of exenatide's reduction in all-cause death
What the researchers found
Using a validated diabetes outcomes model and participant-level data from EXSCEL, the researchers simulated how much of exenatide's cardiovascular benefits should result from its improvements in HbA1c, blood pressure, heart rate, LDL cholesterol, triglycerides, and weight.
The model could only explain modest proportions of the observed benefits: 29% for MACE (major adverse cardiovascular events), 15% for all-cause mortality, 18% for cardiovascular death, and 29% for stroke. The model explained more for hospitalization for heart failure (67%) and myocardial infarction (200% — meaning risk factors predicted more benefit than was actually observed for MI). Mediation analysis confirmed that changes in these conventional risk factors up to 12 months did not mediate the reduction in all-cause mortality.
Why it matters
This analysis addresses one of the biggest questions in GLP-1 pharmacology: how do these drugs reduce cardiovascular events and death? If the benefits came mainly from improving blood sugar and cholesterol, then any drug achieving those improvements should have similar heart benefits. But the finding that 70-85% of the cardiovascular benefit is unexplained by traditional risk factors suggests GLP-1 drugs have direct cardioprotective effects — potentially through anti-inflammatory pathways, improved endothelial function, or direct cardiac effects. This changes how we think about prescribing these drugs and who should receive them.
The numbers in context
MACE reduction: 29% explained · ACM: 15% explained · CV death: 18% explained · Stroke: 29% explained · hHF: 67% explained · MI: 200% explained · Risk factors did not mediate ACM reduction
How the study worked
This was a post hoc analysis of the EXSCEL trial (Exenatide Study of Cardiovascular Event Lowering), which randomized patients with type 2 diabetes to once-weekly exenatide or placebo. The researchers entered individual participant risk factor values over time into a validated type 2 diabetes clinical outcomes model to estimate expected cardiovascular event rates based on observed risk factor changes. They then compared these model-predicted outcomes with the actual trial results across six endpoints. They also performed mediation analysis using Cox regression to evaluate whether specific risk factor changes mediated the effect on all-cause mortality.
Who was studied
EXSCEL trial participants with type 2 diabetes (original trial n=14,752)
What this study cannot tell us
This is a post hoc analysis, meaning these questions were explored after the trial was completed rather than being pre-specified. The validated outcomes model, while well-established, may not capture all pathways through which risk factor changes affect outcomes. Risk factor changes were measured only up to 12 months, so longer-term effects may differ. The analysis cannot identify what the unexplained mechanisms actually are — it can only show that traditional risk factors don't account for the full benefit.
How to read the evidence
Rated 'strong' because this is a rigorous post hoc analysis of a large randomized controlled trial (EXSCEL, n=14,752) using a validated outcomes model and mediation analysis, published in a respected cardiology journal with prominent investigators.
When this study was published
Published in 2025 in Cardiovascular Diabetology. This is a very current analysis that adds to the evolving understanding of how GLP-1 drugs protect the heart, building on the original EXSCEL results published in 2017.
The bigger picture
This study adds to growing evidence that GLP-1 drugs' cardiovascular benefits go far beyond metabolic improvements. Similar findings have emerged from analyses of semaglutide trials (SELECT, SUSTAIN-6) — the heart protection consistently exceeds what risk factor changes alone would predict. This has fueled intense research into GLP-1's direct effects on blood vessels, heart muscle, and inflammation. It also supports the argument that GLP-1 drugs should be considered cardiovascular medications, not just diabetes or weight loss drugs.
Questions still open
- What specific biological mechanisms account for the 70-85% of GLP-1 cardiovascular benefit that can't be explained by traditional risk factor improvements?
- Do different GLP-1 drugs (exenatide, semaglutide, liraglutide) share the same unexplained cardioprotective mechanisms, or do they differ?
- Should GLP-1 drugs be prescribed for cardiovascular protection even in patients whose traditional risk factors are already well-controlled?
Common questions
If GLP-1 drugs protect the heart, how do they actually do it?
What was the EXSCEL trial?
Read the original research
Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis.
Cardiovascular diabetology, 24(1), 347
Citation
Coleman, Ruth L; Adler, Amanda I; Mentz, Robert J; Fudim, Marat; Sattar, Naveed; Holman, Rury R. (2025). Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis.. Cardiovascular diabetology, 24(1), 347. https://doi.org/10.1186/s12933-025-02866-7